Rahul Kalhapure

Dr. Rahul Kalhapure


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SSSandeep J. Sonawane
Sandeep J. Sonawane
RKRahul Kalhapure
Rahul Kalhapure
TGThirumala Govender
Thirumala Govender

1 March 2015 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
RKRahul Kalhapure
Rahul Kalhapure
NSNadia Suleman
Nadia Suleman
CMChunderika Mocktar
Chunderika Mocktar
NSNasreen Seedat
Nasreen Seedat
TGThirumala Govender
Thirumala Govender

1 December 2015 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
RKRahul Kalhapure
Rahul Kalhapure
SSSandeep J. Sonawane
Sandeep J. Sonawane
DSDhiraj R. Sikwal
Dhiraj R. Sikwal
MJMahantesh Jadhav
Mahantesh Jadhav
SRSanjeev Rambharose
Sanjeev Rambharose
TGThirumala Govender
Thirumala Govender

1 May 2014 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
RKRahul Kalhapure
Rahul Kalhapure
CMChunderika Mocktar
Chunderika Mocktar
DSDhiraj R. Sikwal
Dhiraj R. Sikwal
SSSandeep J. Sonawane
Sandeep J. Sonawane
MKMuthu K. Kathiravan
Muthu K. Kathiravan
TGThirumala Govender
Thirumala Govender

19 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RJRijo John
Rijo John
JMJasmin Monpara
Jasmin Monpara
SSShankar Swaminathan
Shankar Swaminathan
RKRahul Kalhapure
Rahul Kalhapure
Lipid nanoparticles (LNPs) have gained prominence as primary carriers for delivering a diverse array of therapeutic agents. Biological products have achieved a solid presence in clinical settings, and the anticipation of creating novel variants is increasing. These products predominantly encompass therapeutic proteins, nucleic acids and messenger RNA. The advancement of efficient LNP-based delivery systems for biologics that can overcome their limitations remains a highly favorable formulation strategy. Moreover, given their small size, biocompatibility, and biodegradation, LNPs can proficiently transport therapeutic moiety into the cells without significant toxicity and adverse reactions. This is especially crucial for the existing and upcoming biopharmaceuticals since large molecules as a group present several challenges that can be overcome by LNPs. This review describes the LNP technology for the delivery of biologics and summarizes the developments in the chemistry, manufacturing, and characterization of lipids used in the development of LNPs for biologics. Finally, we present a perspective on the potential opportunities and the current challenges pertaining to LNP technology.

1 August 2018 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Pradeep Kumar BollaPradeep Kumar Bolla
Pradeep Kumar Bolla
VRVictor A. Rodriguez
Victor A. Rodriguez
RKRahul Kalhapure
Rahul Kalhapure
CKChandra Sekhar Kolli
Chandra Sekhar Kolli
SASweta Andrews
Sweta Andrews
JRJwala Renukuntla
Jwala Renukuntla